Related Experiment Videos
Continuous venovenous hemodiafiltration in neonatal onset hyperammonemia
Takehiko Hiroma1, Tomohiko Nakamura, Masanori Tamura
1Division of Neonatology, Medical Engineering, Nagano Children's Hospital, Toyoshina, Nagano, Japan.
American Journal of Perinatology
|May 16, 2002
Summary
Continuous hemodiafiltration (CHDF) effectively treated neonatal hyperammonemia from metabolic disorders. This safe method rapidly reduced ammonia levels and corrected acidosis in infants.
Area of Science:
- Neonatology
- Pediatric Nephrology
- Metabolic Disorders
Background:
- Neonatal-onset hyperammonemia due to metabolic disorders presents a critical challenge.
- Prompt ammonia removal is crucial for preventing severe neurological damage.
Purpose of the Study:
- To evaluate the efficacy and safety of continuous hemodiafiltration (CHDF) in treating neonatal hyperammonemia.
- To describe the technical adaptations required for CHDF in neonates.
Main Methods:
- Four neonates with metabolic disorder-induced hyperammonemia were treated with CHDF.
- Veno-venous CHDF was performed using a 7-Fr double lumen catheter.
- Specialized neonatal circuits, nafamostat mesilate anticoagulation, and a circuit warmer were employed.
Main Results:
- CHDF achieved prompt and stable removal of serum ammonia.
- Serum ammonia levels decreased below 200 microg/dL within 30 hours.
- Lactic acidosis was immediately corrected, and circulation remained stable throughout treatment.
Conclusions:
- CHDF is a highly effective and safe treatment for fluminant neonatal hyperammonemia.
- Technical modifications enable successful application of CHDF in the neonatal population.
- CHDF offers a life-saving intervention for severe metabolic crises in newborns.